GF Xinde's bcc International Life Sciences Fund: IPO project accounted for 12% of the total U.S. biotech IPO in the first half of 2018

Since its establishment in less than two years, the Bay City Capital International Life Sciences Fund (established by GF Xinde) has successfully achieved four IPOs in Nasdaq. Now the fifth project is in the process of IPO. Let us look forward to the foreseeable future.
Besides, more than 80% of the projects invested by the BCC International Life Sciences Fund of GF Xinde are in compliance with the listing rules of the Hong Kong Stock Exchange for biotech companies. In addition, the Hong Kong Stock Exchange provides more opportunities for the development of life sciences companies. The HK Stock Exchange has recently undergone significant changes, creating more chances for life sciences enterprises (including our funded ocmpanies) to start IPO in Hong Kong.
Following the great trend of the development of life sciences industry, GF Xinde's investment strategy "Global Resource & Chinese Power" has been accepted and recognized by the world life sciences industry.